SCHEMBL23985993

SCHEMBL23985993

CCOC(=O)c1conc1CCC(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.39
KDM4E B2RXH2 2/20 0.39
TSHR P16473 2/20 0.39
HDAC4 P56524 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HSP90AA1 P07900 1/20 0.37
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPK1 P28482 2/20 0.35
GAA P10253 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
MAOB P27338 1/20 0.35
MLYCD O95822 1/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA7 P43166 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30322918 0.86 CFTR (0.33) KDM4ETSHRALDH1A1MEN1KMT2A
SCHEMBL22213850 0.84 TSHR (0.42) IDO1KDM4ETSHRHSP90AA1ALDH1A1
SCHEMBL22213880 0.82 TSHR (0.43) KDM4ETSHRHSP90AA1ALDH1A1MEN1
SCHEMBL25526800 0.81 TSHR (0.42) KDM4ETSHRHSP90AA1ALDH1A1MEN1
SCHEMBL285934 0.81 HSP90AA1 (0.43) KDM4ETSHRHSP90AA1ALDH1A1MEN1
SCHEMBL22213907 0.81 TSHR (0.44) IDO1KDM4ETSHRHSP90AA1ALDH1A1
SCHEMBL25745095 0.81
SCHEMBL5275787 0.81 TSHR (0.47) KDM4ETSHRHSP90AA1ALDH1A1MEN1
SCHEMBL22439707 0.80 HDAC4 (0.40) IDO1KDM4ETSHRHDAC4HDAC6
SCHEMBL11554506 0.80 TSHR (0.49) KDM4ETSHRALDH1A1HSD17B10MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 US disclosed
US-20230242537-A1 IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA N.V. (BE) 2023-08-03 US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 US disclosed
US-11691979-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
EP-4143193-A1 IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 JANSSEN Pharmaceutica NV (BE) 2023-03-08 EP disclosed
EP-4143195-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 Janssen Pharmaceutica NV (BE) 2023-03-08 EP disclosed
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN RESEARCH & DEVELOPMENT, LLC 2022-12-22 US disclosed
WO-2021220183-A1 IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2021-11-04 WO disclosed
WO-2021222404-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN BIOTECH, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691979-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 IDO1 246/4885KDM4E 2583/4885TSHR 481/4885
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 IDO1 246/4885KDM4E 2583/4885TSHR 481/4885
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 IDO1 246/4885KDM4E 2583/4885TSHR 481/4885
US-11702422-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 IDO1 246/4885KDM4E 2583/4885TSHR 481/4885
US-20230242537-A1 IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 IL17A, IL23R, IL2 IDO1 502/4885KDM4E 2283/4885TSHR 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.